本文選題：首發(fā)精神分裂癥 + 非典型抗精神病藥　； 參考：《中國新藥雜志》2017年17期

【摘要】：目的:運用藥物經(jīng)濟學(xué)評價的方法,對利培酮、奧氮平、喹硫平、齊拉西酮、阿立哌唑5種藥品一線治療首發(fā)精神分裂癥進行成本效果分析,為臨床治療首發(fā)精神分裂癥用藥提供參考和建議。方法:通過單組率Meta分析獲得有效率指標(biāo),對5種藥品治療首發(fā)精神分裂癥構(gòu)建決策樹模型進行成本效果分析,并進行單因素敏感性分析和概率敏感性分析。結(jié)果:通過增量成本效果分析,喹硫平、奧氮平、阿立哌唑為劣勢方案被排除;齊拉西酮相比于利培酮的增量成本效果比(incremental cost effectiveness ratio,ICER)為25 194.09元。敏感性分析與基礎(chǔ)分析結(jié)果基本一致。結(jié)論:臨床治療首發(fā)精神分裂癥時可以根據(jù)患者的意愿支付值(willingness-to-pay,WTP)選擇最優(yōu)方案。若WTP低于ICER,則優(yōu)先使用利培酮;若高于ICER,則優(yōu)先使用齊拉西酮。但就我國國情而言,ICER值相對較高,利培酮對絕大多數(shù)中國患者更具有經(jīng)濟性,推薦臨床優(yōu)先使用。
[Abstract]:Objective: to evaluate the cost-effectiveness of risperidone, olanzapine, quinthiapine, ziprasidone and aripiprazole in first-line treatment of first-line schizophrenia. To provide reference and advice for clinical treatment of first episode schizophrenia. Methods: the effective rate index was obtained by single-group meta-analysis. The cost-effect analysis was performed on the decision tree model of five kinds of drugs for first-episode schizophrenia, and the single-factor sensitivity analysis and probability sensitivity analysis were carried out. Results: according to the incremental cost effect analysis, quinolipine, olanzapine and aripiprazole were excluded, and the incremental cost effect of ziprasidone compared with risperidone was 25 194.09 yuan. The results of sensitivity analysis are consistent with those of basic analysis. Conclusion: the optimal scheme can be selected according to the patient's will to pay for the first episode schizophrenia. Risperidone is preferred if WTP is lower than ICERand ziprasidone is preferred if WTP is higher than ICER. However, the ICER value of risperidone is relatively high in our country. Risperidone is more economical for most Chinese patients.
【作者單位】： 中國藥科大學(xué)國際醫(yī)藥商學(xué)院;
【分類號】：R956

【相似文獻】

相關(guān)期刊論文 前2條

1 陳春發(fā),胡鵬,王暉;低劑量利培酮治療首發(fā)精神分裂癥的臨床研究[J];臨床精神醫(yī)學(xué)雜志;1999年04期

2 甘景梨,白照慶,王世堯,張萬恒,呂存生,劉欣喜;利培酮與氯氮平治療首發(fā)精神分裂癥的對照研究[J];中國民政醫(yī)學(xué)雜志;1999年01期

，

本文編號：2013487